Molbio Diagnostics Achieves Rs 52.7 Cr Profit in First Quarter Post-IPO
Molbio Diagnostics reports a Rs 52.7 crore profit in Q1, reversing a loss of Rs 23.94 crore from last year, following a successful IPO.
Molbio Diagnostics, a newly listed entity on the stock exchange, has reported a significant turnaround in its financial performance for the first quarter ending June 2026. The company posted a profit of Rs 52.74 crore, a substantial reversal from the Rs 23.94 crore loss recorded in the same period last year. This improvement comes on the heels of the company’s successful Initial Public Offering (IPO), which raised approximately Rs 940 crore.
Strong Financial Performance Post-IPO
The company’s total income surged to Rs 411.48 crore in the first quarter of the current fiscal year, up from Rs 100.47 crore in Q1 FY26. This growth was primarily driven by increased demand for its Truenat test kits. According to the company’s regulatory filing, the volume of Truenat test kits sold rose dramatically to 62.4 lakh units, compared to just 7.9 lakh units in the corresponding period of the previous year.
Truenat Test Kits Drive Revenue
Truenat, Molbio Diagnostics’ flagship product, is designed to quickly and accurately detect a wide range of infectious diseases at the point of care. The increased adoption and consumption of these test kits have been pivotal in the company’s improved financial performance. The company was officially listed on the stock exchange on August 17, marking a new phase in its corporate journey.
Leadership Remarks on Financial Milestone
Sriram Natarajan, Executive Director & Chief Executive Officer of Molbio Diagnostics, expressed optimism about the company’s future. "FY27 is a milestone year for Molbio, marking our transition to a listed company. We have begun the year on a strong note, with healthy growth across both revenue and profitability in Q1," he stated.
The company’s strong financial results and successful IPO suggest a promising trajectory as it continues to capitalize on the growing demand for diagnostic solutions. This performance is expected to bolster investor confidence and support Molbio Diagnostics’ strategic growth plans in the diagnostics sector.